Could a common cold sore drug ease facial pain? new trial investigates
NCT ID NCT07673549
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial compares three treatments for idiopathic trigeminal neuralgia, a condition causing severe facial pain. One group gets standard carbamazepine alone, another adds the antiviral acyclovir, and the third adds the anti-inflammatory celecoxib. The goal is to see which combination provides better pain relief and improves quality of life over 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Carbamazepine plus acyclovir or celecoxib
- What this could lead to
- If successful, this could identify a more effective combination therapy for managing trigeminal neuralgia pain, potentially reducing daily medication needs and improving quality of life.
- What could go wrong
- This is a relatively small, early-stage trial, and the added drugs may not provide extra benefit over carbamazepine alone. Side effects from the combinations are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC TRIGEMINAL NEURALGIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.